A recent FiercePharma article discussed the recall of Pfizer’s menopause drug, Duavee. The company voluntarily recalled two batches of the drug, which is marketed as Duavive abroad, over concerns of faulty packaging that might have reduced efficacy. A flaw in the drug’s foil laminate pouch allows oxygen to pass through, lowering the dissolution rate of the active pharmaceutical ingredient, bazedoxifene acetate.
This is just the latest in Pfizer’s ongoing troubles with the menopause drug. Just weeks ago, the company recalled 11 lots of the drug in the U.S., and two in Canada in late May.